New Service for Circulating Tumor Cell Analysis Now Available
|
By LabMedica International staff writers Posted on 18 Feb 2014 |
|
Image: Fluxion’s IsoFlux system with cutting-edge technology for circulating tumor cell enrichment (Photo courtesy of Fluxion Bioscences).
A new clinical sample procurement capability, including fresh blood draws from a wide range of cancer indications and tumor subtype profiles, improves circulating tumor cell analysis services.
The cutting-edge technology of the IsoFlux system for circulating tumor cell (CTC) enrichment and analysis is among the systems from Fluxion Biosciences (South San Francisco, CA, USA) designed to replace laborious and difficult assays by providing intuitive, easy-to-use instruments for cell-based analysis. Fluxion now also has the new capability to include full-service clinical sample procurement to expand its IsoFlux Discovery Services offering. Fluxion has been providing a broad range of analytic services using its IsoFlux system for CTC enrichment, including quantitative polymerase chain reaction (qPCR) and next-generation sequencing (NGS)-based assays. With this new capability, Fluxion can now also provide clinical sample procurement that includes fresh blood draws from a wide range of cancer indications and tumor subtype profiles, such as Her2+, KRAS+, and EGFR+ samples.
The services are available to diagnostic, biopharmaceutical, and research institutes that wish to conduct CTC studies with clinical samples on a contract basis. These are provided out of Fluxion’s South San Francisco reference laboratory using cutting-edge IsoFlux technology as well as the CTC experience of Fluxion scientific personnel. With this new offering, clients can now specify the number and types of clinical samples they wish to analyze and have them included in the study without having to set up clinical agreements. The clinical samples are shipped overnight to Fluxion’s laboratory and processed the day of arrival. Each sample is highly annotated with clinical information and obtained under Institutional Review Board (IRB) consent.
“After running our Discovery Services for some time now, we realized that obtaining prospective clinical samples for CTC studies is a major bottleneck for our clients. Setting up clinical agreements, obtaining IRB approval, and waiting for patient recruitment can slow things down considerably,” said Mike Schwartz, program director at Fluxion; “This new addition to our service offering will dramatically increase the speed of discovery for our clients, not to mention make it easier to source an entire study from a single vendor.”
Related Links:
Fluxion Biosciences
Isoflux
The cutting-edge technology of the IsoFlux system for circulating tumor cell (CTC) enrichment and analysis is among the systems from Fluxion Biosciences (South San Francisco, CA, USA) designed to replace laborious and difficult assays by providing intuitive, easy-to-use instruments for cell-based analysis. Fluxion now also has the new capability to include full-service clinical sample procurement to expand its IsoFlux Discovery Services offering. Fluxion has been providing a broad range of analytic services using its IsoFlux system for CTC enrichment, including quantitative polymerase chain reaction (qPCR) and next-generation sequencing (NGS)-based assays. With this new capability, Fluxion can now also provide clinical sample procurement that includes fresh blood draws from a wide range of cancer indications and tumor subtype profiles, such as Her2+, KRAS+, and EGFR+ samples.
The services are available to diagnostic, biopharmaceutical, and research institutes that wish to conduct CTC studies with clinical samples on a contract basis. These are provided out of Fluxion’s South San Francisco reference laboratory using cutting-edge IsoFlux technology as well as the CTC experience of Fluxion scientific personnel. With this new offering, clients can now specify the number and types of clinical samples they wish to analyze and have them included in the study without having to set up clinical agreements. The clinical samples are shipped overnight to Fluxion’s laboratory and processed the day of arrival. Each sample is highly annotated with clinical information and obtained under Institutional Review Board (IRB) consent.
“After running our Discovery Services for some time now, we realized that obtaining prospective clinical samples for CTC studies is a major bottleneck for our clients. Setting up clinical agreements, obtaining IRB approval, and waiting for patient recruitment can slow things down considerably,” said Mike Schwartz, program director at Fluxion; “This new addition to our service offering will dramatically increase the speed of discovery for our clients, not to mention make it easier to source an entire study from a single vendor.”
Related Links:
Fluxion Biosciences
Isoflux
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Latest Technology News
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
- AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
- AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
- AI Model Achieves Breakthrough Accuracy in Ovarian Cancer Detection
- Portable Biosensor Diagnoses Psychiatric Disorders Using Saliva Samples
- Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement
- Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
Channels
Clinical Chemistry
view channel
Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
People with diabetes often need to measure their blood glucose multiple times a day, most commonly through finger-prick blood tests or implanted sensors. These methods can be painful, inconvenient, and... Read more
POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
Pseudomonas aeruginosa is a major cause of hospital-acquired and ventilator-associated pneumonia, particularly in lung transplant recipients and patients with structural lung disease. Its ability to form... Read more
Molecular Diagnostics
view channel
Endometriosis Blood Test Could Replace Invasive Laparoscopic Diagnosis
Endometriosis affects an estimated 1 in 10 women globally, yet diagnosis can take 7 to 10 years on average due to the invasive nature of laparoscopy and lack of accurate, non-invasive tests.... Read more
World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device
Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read more
Rapid Diagnostic Breakthrough Simultaneously Detects Resistance and Virulence in Klebsiella Pneumoniae
Antibiotic resistance is a steadily escalating threat to global healthcare, making common infections harder to treat and increasing the risk of severe complications. One of the most concerning pathogens... Read more
Hematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
Colon cancer remains a major cause of cancer-related illness, with many patients facing relapse even after surgery and chemotherapy. Up to 40% of people with stage III disease experience recurrence, highlighting... Read more
Microbiology
view channel
New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
Urinary tract infections affect around 152 million people every year, making them one of the most common bacterial infections worldwide. In routine medical practice, diagnosis often relies on rapid urine... Read more
Breakthroughs in Microbial Analysis to Enhance Disease Prediction
Microorganisms shape human health, ecosystems, and the planet’s climate, yet identifying them and understanding how they are related remains a major scientific challenge. Even with modern DNA sequencing,... Read more
Pathology
view channel
AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
Head and neck cancers are among the most aggressive malignancies worldwide, with nearly 900,000 new cases diagnosed each year. Monitoring these cancers for recurrence or relapse typically relies on tissue... Read more
Industry
view channel
BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) has entered into a strategic collaboration with the Institute for Immunology and Immune Health (I3H, Philadelphia, PA, USA) at the University... Read more
